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The single protein encoded by Abelson murine leukemia virus is a fusion of sequence from the retroviral gag
genes with the v-abl sequence. Deletion of most of the gag region from the transforming protein results in a
virus capable of transforming fibroblasts but no longer capable of transforming lymphoid cells. Smaller
deletions in gag reveal that p15 gag sequences are responsible for this effect, whereas deletion of p12 sequences
had no effect on lymphoid transformation. In transformed fibroblasts, p15-deleted and normal proteins had
similar activities and subcellular localization. When the p15-deleted genome was introduced into previously
transformed lymphoid lines, its protein product exhibited a marked instability. The tyrosine-specific
autophosphorylation activity per cell was less than 1/20th that of the nondeleted protein. Although pulse-la-
beling showed that the p15-deleted protein was synthesized efficiently, immunoblotting demonstrated that its
steady-state level was less than 1/10th that of the nondeleted Abelson protein. The specific instability of the
p15-deleted protein in lymphoid cells explains the requirement of these sequences for lymphoid but not
fibroblast transformation.
Abelson Murine Leukemia virus (A-MuLV) is a replica-
tion-defective retrovirus capable of transforming fibroblast
cells in vitro (28) and lymphoid cells both in vivo and in vitro
(1, 26). The virus arose through recombination between
Moloney-MuLV (M-MuLV), a replication-competent retro-
virus, and c-abl, a gene normally expressed in many cells (7,
19, 31, 37, 38). The A-MuLV genome expresses a single gene
product partially derived from each parent (23, 44). It
contains 30 kilodaltons (kd) of M-MuLV gag-encoded se-
quence at its N terminus, followed by variable amounts of
v-abl-derived sequence. The gag gene of M-MuLV encodes
the viral core antigens in the form of a precursor protein,
Pr65gag, which contains p15, pi2, p30, and plO, in that order.
Pr65gag is cleaved into these products during maturation of
the virion at the cell surface. The A-MuLV protein contains
p15, p12, and a small part of p30 fused to the v-abl-encoded
sequence.
The A-MuLV protein displays a protein-tyrosine kinase
activity (42) which is apparently essential to the ability of the
virus to transform cells (43). Mutations in the N terminus of
v-abl abolish the kinase activity, as well as the transforma-
tion activity (20a; J. J.-Y. Wang and D. Baltimore, J. Biol.
Chem., in press). The Rous sarcoma virus transforming gene
product, pp60sc, as well as that of several other oncogenes
(12, 13, 16) and growth factor receptor proteins (6, 11, 15,
34), has a protein-tyrosine kinase activity. Furthermore,
these oncogenes and the epidermal growth factor receptor
have extensive amino acid homology through a section of
their genes which encodes the tyrosine kinase activity (3, 5).
There are many variants of A-MuLV containing different
segments of v-abl. The largest variant, A-MuLV[P160],
encodes a 160-kd protein, including 130 kd encoded by v-abl
(9, 27). Only the N-terminal 45 kd of v-abl protein, contain-
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ing the kinase domain and amino acid homology to pp60src,
is required for fibroblast transformation (21, 22). Although
deletion of the C terminus of v-abl reduces the lymphoid
transformation efficiency (27, 39), we show here that vari-
ants with the N-terminal 60 kd of v-abl protein retain the
ability to transform lymphoid cells. For ease of reference,
we call any v-abl-containing protein an Abelson protein.
Deletion of all of the gag sequences in A-MuLV, except
for the first 34 amino acids, resulted in a virus which still
transformed NIH/3T3 fibroblasts efficiently (21). Surpris-
ingly, however, the deletion totally abolished the ability of
the virus to transform lymphoid cells. Here, we report the
effect of smaller deletions in gag. Deletion in p12 had no
effect, whereas deletion in p15 abolished lymphoid-trans-
forming activity. As we have not been able to detect any
biochemical differences in the p15-deleted protein in trans-
formed fibroblast cells, we introduced the p15-deleted virus
into previously transformed lymphoid cells to study its
properties in this specific cell type. We find a marked
instability of the deleted protein specific to this cell type,
resulting in drastically lower steady-state levels of the pro-
tein.
MATERIALS AND METHODS
Cells and viruses. Normal and A-MuLV-transformed
NIH/3T3 cells were grown in Dulbecco modified Eagle's
medium with 10% calf serum. A-MuLV titers were deter-
mined by focus formation on NIH/3T3 cells (28). Lymphoid
cells were grown in RPMI 1640 medium supplemented with
10% fetal calf serum and 50 ,uM 2-mercaptoethanol. In vitro
bone marrow transformation in agar and liquid have been
described (25, 26). Transfections of NIH/3T3 cells were as
described (41) and modified (21).
Infections of 70Z/3 and 2M3 cells were performed by
resuspending 104 cells in 1.0 ml of a 1:1 dilution of a virus
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stock (with 8 ,ug of polybrene per ml) from either N2 or
NAp15-1 cells. The titers of these stocks were roughly 5 x
105 focus-forming units per ml. After 1.5 h of incubation with
virus at 37°C the cells were single-cell cloned into microtiter
wells. Single-cell clones were picked after 7 days from
96-well plates with less than 15 positive wells.
Cellular DNA and RNA. The preparation of total cellular
DNA, restriction enzyme digestions, gel electrophoresis,
and transfer to nitrocellulose (32) were all previously de-
scribed (9). 32P-labeled probes were prepared by nick trans-
lation (24).
Total cellular RNA was prepared by the guanidinium
thiocyanate method (4), treated with glyoxal, and fraction-
ated by electrophoresis through an agarose gel (18). The gel
was transferred to nitrocellulose and hybridized with a
nick-translated v-abl-specific probe.
Labeling, immunoprecipitation, and autophosphorylation.
Cells were labeled with [35S]methionine at 100 ,uCi/ml in
methionine-free Dulbecco modified Eagle medium. Cells
were extracted in phospholysis buffer (PLB; 10 mM sodium
phosphate [pH 7.5], 0.1 M NaCl, 1% Triton X-100, 0.5%
deoxycholate, 0.1% sodium dodecyl sulfate [SDS]), im-
munoprecipitated, and separated by electrophoresis through
SDS-polyacrylamide gels as detailed elsewhere (44). Sam-
ples were normalized for trichloroacetic acid-precipitable
radioactivity in each cell lysate before immunoprecipitation.
A mouse monoclonal antibody against M-MuLV p12 was
provided by Bruce Cheeseboro. A mouse monoclonal anti-
body to M-MuLV p15 was from Leslie Schiff-Maker and
Naomi Rosenberg. R-anti-abl, a rabbit antiserum against
v-abl protein expressed in bacteria, was provided by Jean
Wang.
In vitro autophosphorylation reactions were essentially as
described (42). Briefly, samples were normalized for cell
number, extracted, and immunoprecipitated. The immune
complexes were collected with 25 [lI of 50% protein A-
Sepharose (Pharmacia Fine Chemicals, Inc.) and washed
three times in lysis buffer. The pellets were then washed two
times in 50 mM Tris (pH 8) and resuspended in 50 RI of 20
mM Tris (pH 8)-10 mM MnCl2-0.2 RI of 200 mCi of[,y-32P]ATP (ICN East Pharmaceuticals). The autophospho-
rylation reaction was allowed to proceed for 10 min on ice.
The pellet was then washed once with 1.0 ml of 50 mM Tris
(pH 8) and resuspended in SDS-sample buffer (67 mM Tris
[pH 6.8], 2% SDS, 10% glycerol, 5 mM EDTA, 20 mM
dithiothreitol, bromophenol blue). The samples were boiled
and fractionated by electrophoresis through an SDS- poly-
acrylamide gel in the standard fashion.
Immunoblotting. A-MuLV proteins were analyzed by im-
munoblotting essentially as described (33). Samples were
normalized for cell number, extracted in 10 mM Tris (pH
7.5)-0.1 M NaCl-1% Triton X-100-0.5% deoxycholate-0.1%
SDS for 10 min on ice, and clarified for 15 min at 13,000 x g.
One-half volume of 3 x SDS-sample buffer was added to the
supernatants, boiled for 5 min, and fractionated by elec-
trophoresis through a 7% SDS-polyacrylamide gel. The
proteins were then transferred to nitrocelluose by using an
electroblot apparatus (Bio-Rad Laboratories) at 275 mA for
2 h in 192 mM glycine-25 mM Tris-hydrochloride-20%
(vol/vol) methanol. After transfer the filter was soaked for 1
h at room temperature in phosphate-buffered saline (PBS;
pH 7.5) with 3% bovine serum albumin and 0.05% Tween 20
(blocking buffer), followed by 1 h at room temperature in
blocking buffer containing a 1:1,000 dilution of R-anti-abl.
The filter was then washed three times, 10 min each time, in
PBS. As a second antibody, goat anti-rabbit immunoglobulin
G conjugated to peroxidase (Cappel Laboratories) was used.
The filter was incubated at room temperature for 30 min in
blocking buffer containing a 1:1,000 dilution of the second
antibody, The filter was again washed three times, 10 min
each time. The specific signal was developed by placing the
gel in 50 ml of water containing 50 mg of 3-3'-
diaminobenzidine, 0.5 g of imidazole, and 50 pl of H202.
When the signal was dark enough, the developer was stopped
by washing the filter in PBS.
Cellular fractionation. Cells were normalized for number,
washed once in PBS, resuspended in 1.0 ml of cold hypo-
tonic Dounce buffer (5 mM KCI, 1 mM MgCl2, 20 mM
HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid] [pH 7.0]), and allowed to swell for 10 min on ice. The
samples were then Dounce homogenized 30 times and passed
through a 25-gauge needle 10 times. This lysate was centri-
fuged at 1,000 x g for 5 min to remove nuclei and unlysed
cells. The supernatant was centrifuged at 100,000 x g at 4°C
for 30 min. The pellet (P100) was resuspended in lx PLB,
whereas 1Ox PLB was added to the supernatant (S100).
Each fraction was immunoprecipitated and analyzed for
autophosphorylation activity.
Plasmid constructions. All restriction enzymes (except
EcoRI) and Bal 31 exonuclease were from New England
Biolabs, Inc. EcoRI and the Klenow fragment of Escherichia
coli polymerase I were from Boehringer Mannheim Bio-
chemicals. Linker DNA and T4 DNA ligase were from
Collaborative Research, Inc. Ampicillin-resistant colonies of
E. coli HB101 were screened by rapid DNA preparation (14)
and restriction digests. DNA was purified from agarose gels
by the glass bead method (36). The various plasmids were
constructed as follows.
(i) pABX2. pABX2 is a proviral plasmid containing a
genome truncated at the 3' end of v-abl at a XhoI site. This
plasmid is the same as pABX (21), except that sequences at
the 3' end of the virus, corresponding to the HpaI to ClaI
sites of M-MuLV, have been deleted. This removes the
possibility of the A-MuLV protein translating in frame with
these sequences, which code for a part of piSE of M-MuLV.
In addition the EcoRI site, at the junction of pBR322 and
cellular flanking sequences, has been deleted.
(ii) pXApl5. A deletion was made in pXAplS by placing an
EcoRI 12-base-pair linker at two sites. The plasmid was
digested with either BstEII or Narl. The cohesive ends were
blunted with the Klenow fragment of E. coli polymerase I,
and the EcoRI linkers were ligated on. Excess linkers were
removed by EcoRI digestion. The DNA was also digested
with a second enzyme and gel purified. The plasmid was
reconstructed by three-part ligation of (i) HindIII-to-BstEII
(changed to an EcoRI site by the linker), (ii) Narl (changed
to an EcoRI site by the linker)-to-BglII, and (iii) BglII-to-
HindlIl fragments. This deletes amino acids 38 to 138 of
gag, where the start codon methionine is counted as number
1. Three amino acids (Pro-Asn-Ser) are inserted at the
deletion junction due to the linker DNA.
(iii) pXApl2. pXApl2 deletes amino acids 163 to 228 of
gag, inserting three amino acids at the junction (Glu-Phe-
Gly). This deletion was derived by using two previously
constructed plasmids. One, pH3, contains an EcoRI linker
insertion (Prywes et al., submitted for publication). The
second contains a Bal 31 exonuclease-generated deletion
with an EcoRI linker at the deletion junction. Piecing sec-
tions of these two plasmids together results in the deletion
described above.
(iv) pABN2. pABN2 is exactly like pABX2, except for the
end of its v-abl region. An EcoRI linker was placed at the
J. VIROL.













FIG. 1. Genomes of A-MuLV viruses used to test for the effect of gag deletions on lymphoid transformation. The deleted genomes of
A-MuLV viruses, along with the names of the plasmids constructed to contain these genomes and the cell lines containing the genomes, are
shown. The ability of the viruses to transforn fibroblast and lymphoid cells is also indicated. All the plasmids transformed NIH/3T3 cells at
an efficiency of ca. 500 foci per ,ug of DNA when cotransfected with M-MuLV DNA. See Table 1 for data on the efficiency of these viruses
in lymphoid transformation.
NarI site 377 bases 5' of the XhoI site used in pABX2. The
position that was the ClaI site of M-MuLV has also been
changed to an EcoRI site. These two EcoRI sites were
ligated together, deleting the 3' 377 bases of v-abl present in
pABX2.
(v) pNApl5. pNApl5 has the exact same deletion as
pXApl5 but in pABN2.
(vi) pNdl. pNdl contains a deletion in pABN2 of amino
acids 114 to 138 of gag, inserting two amino acids (Asn-Ser)
at the junction. The plasmid was generated by treating
pXApl2 with EcoRI and then Bal 31 exonuclease. The
reaction was terminated, the ends were blunted with the
Klenow fragment of E. coli polymerase I, and EcoRI linkers
were ligated on. An EcoRI-to-BglII fragment was gel puri-
fied and ligated to a gel-purified BglII-to-HindIII fragment of
pABN2 and a gel-purified HindIII-to-EcoRI fragment of
pNApl5. This reconstructs the plasmid in a "pABN2"
backbone. The deletion site was sequenced across by the
method of Maxam and Gilbert (17), confirming that the
coding region remains in frame.
(vii) pABGP. pABGP was generated from pABN2. pABN2
was digested partially with PstI, and single-cut linear DNA
was gel purified. This DNA was treated with the Klenow
fragment to remove the single-stranded ends, and EcoRI
linkers were ligated on and then digested with EcoRI to
remove excess linkers and cut the plasmid at the end of v-abl
in pABN2 (corresponding to what was the ClaI site of
M-MuLV). The DNA was then ligated to close the circle and
used to transform E. coli. Ampicillin-resistant colonies were
screened for the EcoRI linker site at the desired PstI site.
RESULTS
p15 and p12 deletions in gag. We have previously shown
that deletion of all but the first 34 amino acids of gag in
plasmid pXgl results in a virus which transforms fibroblastic
cells but has lost the ability to transform lymphoid cells (21).
To localize the sequences in gag required for this effect, we
made smaller deletions within gag. Because of a strong
tendency of A-MuLV strains with a full C-terminal region to
delete during passage of transformed cells (21, 45), plasmid
pABX2, lacking 60 kd of C-terminal v-abl coding sequence,
was the initial starting plasmid for these studies. Two
deletions were made: pXApl5, deleting amino acids 38 to
138 of gag (mainly p15 and 21 bases in p12), and pXApl2,
deleting amino acids 163 to 228 of gag (in p12 and a bit in
p30; Fig. 1 and above). These plasmids were transfected into
NIH/3T3 cells, along with helper virus M-MuLV DNA, to
enhance the transfection efficiency (8). As expected, all
three plasmids transformed NIH/3T3 cells at similar effi-
ciencies of ca. 500 foci per ,ug of DNA.
To produce stocks of virus from the deleted plasmids,
individual foci of transfected, transformed cells were picked
and ascertained to contain the input viral genomes. For the
parental plasmid, pABX2, we were able to isolate a cell line,
X2B, containing only the expected genome as shown by
abl-specific hybridization of cellular DNA cleaved by restric-
tion enzymes in the long terminal repeats and fractionated
by electrophoresis (9, 32) (data not shown). In addition, this
cell line expressed the expected 100-kd Abelson protein.
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FIG. 2. The p15 determinants of the A-MuLV protein are present
in a lymphoid transformant of XAp15-1 virus. Cells were labeled
with [35S]methionine, extracted, and immunoprecipitated with ei-
ther anti-M-MuLV p15 or anti-M-MuLV p12 monoclonal antiserum.
The immunoprecipitates were analyzed by SDS-8% polyacrylamide
electrophoresis as described in the text. The cell lines and antisera
used are indicated above each lane. XAp15-1 is a NIH/3T3 line
transformed by pXApl5. 490-3 is a lymphoid transformant of virus
from XAp15-1.
tained genomes that had undergone further, spontaneous
deletions. Ofthree foci analyzed for pXApl5 and for pXApl2,
none contained only the input genome. Either other forms of
DNA were present along with the expected genome or only
other forms were present (data not shown). We chose cell
lines transformed by pXApl5 and pXApl2, called XAp15-1
and XAp12-1, respectively, which contained the expected
genome, as well as other sizes of proviral DNA. In addition,
by 35S-metabolic labeling of these cells and immunoprecipi-
tation, we confirmed that they contained Abelson proteins
precipitable with specific gag antisera (either anti-p1S or
anti-p12) but not by antisera directed against the deleted
determinants (Fig. 2; data not shown).
Virus was harvested from each of the cell lines, and virus
titers were determined by focus formation on NIH/3T3 cells.
This virus was then tested for lymphoid transformation by
the agar colony method (25). Bone marrow cells from adult
mice were infected with 1 ml of undiluted virus and plated in
agar. Lymphoid colonies were observable at 14 days post-
infection. Transformation by A-MuLV[P160] is included as a
control. Virus from X2B had a lower efficiency than A-
MuLV[P160] but produced easily assayed transformants
(Table 1). The efficiency of transformation by virus from
XAp12-1 was not reduced relative to X2B. Virus from
XAp15-1, however, had virtually no lymphoid transforma-
tion activity.
We did on occasion get one or two lymphoid colonies in an
experiment with the p15-deleted virus of XAp15-1. Cell lines
were derived from these colonies, metabolically labeled with
[35S]methionine, and immunoprecipitated with either anti-
p15 or anti-p12 monoclonal antiserum (one such line, 450-93,
is shown in Fig. 2). Although XAp15-1 contains an Abelson
protein precipitable with anti-p12 but not anti-p15 antiserum
(Fig. 2, lanes 1 and 2), the Abelson protein in 450-93 was
precipitable with both antisera (lanes 3 and 4). Thus, the
protein in 450-93 had regained p15 determinants, suggesting
that these sequences are required for the virus to transform
bone marrow cells. Reappearance of p15 sequences presum-
ably occurred via recombination with the helper virus (which
contains gag sequences), although recombination with en-
dogenous retroviruses is a possibility. We rescued the re-
combinant virus from 450-93 cells and, as expected, it now
transforms bone marrow cells at an efficiency comparable to
that of X2B virus rather than XAp15-1 virus.
Due to the spontaneous deletion problems encountered
with pABX2, we extended these studies by using a slightly
more truncated plasmid, pABN2, which lacks 377 3' bases of
v-abl present in pABX2 (Fig. 1). pABN2 is still capable of
transforming fibroblasts efficiently upon transfection with
M-MuLV, and to date we have not observed any v-abl
deletions in cells transformed by it or any of its derivatives.
Virus from one cell line, N2, derived from a pABN2-induced
focus, could transform lymphoid cells somewhat more effi-
ciently than virus from X2B, and therefore pABN2 appeared
to be a good substrate to examine for the effect of other
deletions.
We made two deletions in pABN2 (Fig. 1). The first,
pNApl5, was the same as that in pXApl5 (deletion of amino
acids 38 to 138); the second, pNdl, deleted amino acids 114
to 138. Both pNApl5 and pNdl transformed NIH/3T3
cells at a frequency comparable to that of pABN2. Two foci
were picked, grown into cell lines, and shown to contain
only the expected genomes. These cell lines, NAp15-1,
Ndl-1, and the parental N2, were metabolically labeled with
[35S]methionine and immunoprecipitated with a mouse anti-
p12 monoclonal antibody. Proteins of the expected size, ca.
TABLE 1. In vitro bone marrow transformation by gag-deleted
variants of Abelson MuLV
Fibroblast No. of lymphoid colonies':
Cell line titer
(FFU/ml)' Per 106 cells Per lOs FFU
Expt 1
54/C12(P160) 3 x 105 145 ± 16 98 ± 11
X2B 5 x 105 5 ± 2 2.0 ± 0.4
XApl5-1 1 x 106 1.0 ± 0.8 0.2 + 0.2
XAp12-1 1 x 105 7 ± 2 14 4
Expt 2
54/C12(P160) 1 x 105 64 ± 4 128 ± 8
N2 6 x 105 27 ± 3 9 1
NAp15-1 8 x 104 <0.13 ± <0.13 <0.31 ± <0.31
Ndl-1 1 x 105 0.4 ± 0.4 0.8 ± 0.8
a The virus titers were determined on NIH/3T3 cells. FFU, Focus-forming
units.
b Nucleated bone marrow cells (2 x 106) were infected with 1.0 ml of virus
and plated in agar. Lymphoid colonies appear at 10 to 14 days postinfection.
The data are given as the average numbers of colonies ± the standard error of
the mean.
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90, 85, and 75 kd, were found in N2, Ndl-1, and NAp15-1,
respectively (Fig. 3). Virus from NAp1S-1, although it had a
high titer on NIH/3T3 cells, had entirely lost its lymphoid-
transforming activity and showed no reversion (Table 1).
The efficiency of lymphoid transformation was also greatly
reduced for virus from Ndl-1. Three of the rare transform-
ants of Ndl-1 virus were analyzed to determine whether the
low level of transformation was due to recombination. All
had the same size of Abelson protein as in Ndl-1, indicating
that they had not reverted (data not shown).
Expression of the p15-deleted virus in Iymphoid cells. To
examine why p15 sequences might be required for lymphoid
transformation, we investigated the various properties of the
deleted proteins expressed in transformed NIH/3T3 cells but
did not find any significant differences from wild-type Ab-
elson proteins. The gag-deleted proteins are still phosphory-
lated on tyrosine and elevate the in vivo phosphotyrosine
level (21). Fractionation of cells into particulate and soluble
fractions by 100,000 x g centrifugation failed to show a
difference: approximately equivalent amounts of the Abe-
lson protein were present in each fraction (data not shown).
Not finding any differences in the protein expressed in
fibroblastic cells, we sought differences directly in lymphoid
cells. Because the p15-deleted genomes do not transform
lymphoid cells and because lymphoid cells do not grow
extensively unless they are transformed, we could not
directly produce a cell that contained only the deleted
genome. We could, however, introduce the genomes non-
selectively into a previously transformned cell line and screen
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FIG. 3. Immunoprecipitation of A-MuLV proteins used to test
for lymphoid transformation. Cells were labeled with [35S]methionine
for 1 h, extracted, immunoprecipitated with an anti-p12 monoclonal
antibody, and analyzed by SDS-8% polyacrylamide electrophoresis
in the standard fashion. The cell lines used are indicated above each







FIG. 4. In vitro kinase activity of A-MuLV proteins in 70Z/3
cells. Cells (106) were extracted, immunoprecipitated with an anti-
p12 monoclonal antibody, and analyzed for in vitro autophosphor-
ylation activity as described in the text. The cell lines used are
indicated above each lane. 7OZ/dl through 70Z/d5 are lines derived
from single-cell clones of 70Z/3 cells infected with the p15-deleted
virus from NAp15-1, whereas 70Z/90A is a single-cell clone infected
with virus from N2 cells, and 70Z/M was infected with only
M-MuLV. N2 and NAp15-1 are transformed fibroblast lines contain-
ing P90 or the p15-deleted P75 A-MuLV proteins. The positions of
the autophosphorylated A-MuLV proteins are marked.
lymphoma cell line 70Z/3 (20). It is slightly more advanced in
its differentiated state than most A-MuLV-transformed lym-
phoid cell lines but has the advantage of lacking any known
transforming virus. These cells were infected with virus
stocks from either N2 or NAp1S-1 at a high multiplicity of
infection and immediately cloned as single cells in microtiter
dishes. The clonal cell lines were then screened for uptake of
A-MuLV by testing immunoprecipitates of cells for au-
tophosphorylation of an Abelson protein (42). Approxi-
mately 50% of the single-cell clones were positive in this
assay. It was immediately evident that in five separate
clones containing the p15-deleted genome, the autophos-
phorylation activity in the deleted P75 protein was 1/20th of
that seen with the fully transforming P90 protein (Fig. 4,
lanes 1 through 5). No autophosphorylation was evident in
immunoprecipitates from a negative control, 70Z/M (lane 7),
which was a single-cell clone of 70Z/3 infected only with
M-MuLV. There was a negligible difference in autophos-
phorylation activity between the transformed fibroblast cells,
N2 and NAp15-1, containing the wild-type and p15-deleted
genomes (lanes 8 and 9).
To determine whether the p15-deleted genome was being
expressed efficiently in 70Z/3 cells, we made total cellular
RNA from 70Z/90A (containing the undeleted virus), 70Z/d2
(containing the p15-deleted virus), and 70Z/M (with no
A-MuLV genome) cells. The RNA was electrophoretically
size fractionated and hybridized to a v-abl-specific probe.
There were roughly equivalent amounts ofA-MuLV RNA in
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FIG. 5. Analysis of RNA from 70Z/3 cells. Total cellular RNA
was prepared from each of the lines, treated with glyoxal, fraction-
ated by electrophoresis through a 1% agarose gel, transferred to
nitrocellulose, and hybridized with the v-abl-specific probe,
pAB1sub9 (37), as described in the text. The cell lines used are
indicated above each lane and described in the legend to Fig. 4. The
position of endogenous c-abl RNA is marked.
70Z/90A and 70Z/d2 (Fig. 5), indicating that there is no block
to expression of the p15-deleted genome in lymphoid cells.
c-abl RNA was also evident in all three lines.
To examine the synthesis and steady-state levels of Ab-
elson proteins in these cells, we performed two experiments.
In one we pulse-labeled the cells with [35S]methionine and
immunoprecipitated the A-MuLV proteins. Both P90 and the
p15-deleted P75 could be detected (Fig. 6). Although P75
was synthesized at a somewhat lower rate, the difference is
not extensive enough to account for the differences in
autophosphorylation activity.
We next used the immunoblotting technique to probe for
the steady-state level of A-MuLV proteins. Lysates were
prepared from each of the cell lines and electrophoresed
through an SDS-7% polyacrylamide gel. The proteins were
transferred to nitrocellulose and probed with a rabbit anti-
body (provided by Jean Wang) directed against v-abl protein
purified from bacteria expressing the 5' 1.2 kilobases of
v-abl. Bound antibody was detected by using a second
antibody stain of goat anti-rabbit immunoglobulin G conju-
gated to peroxidase. P75 and P90 were easily detectable in
the fibroblastic cell lines NAp1S-1 and N2 (Fig. 7, lanes 2 and
3), although at a redued level in NAp1S-1. P90 was also clear
in 70Z/90A (lane 8), but P75 was not detectable in 70Z/d2
(lane 7). We judge that the lower limit of sensitivity is less
than 10% of the P90 level because we could detect P90 when
its lysate was diluted with that of 7OZ/M in a ratio of 1:10
(lane 9). Thus, although P75 is synthesized at appreciable
rates, it does not accumulate to the steady-state levels of
P90, presumably due to the specific instability of this protein
in lymphoid cells.
Attempts to use pulse-chase experiments to demonstrate
this instability directly have been confounded by back-
ground bands that comigrate with P75 and increase in
intensity with chase time. Nonetheless, our estimate from
several experiments is that the half-life of P90 in 70Z/90A is
ca. 7 h, whereas the half-life of P75 in 70Z/d2 is ca. 1 h (data
not shown).
To examine whether the instability was specific to 70Z/3
cells and to directly examine A-MuLV-transformed cells, we
introduced the p15-deleted virus into a lymphoid cell line
already transformed by a competent A-MuLV[P120] strain.
This cell line, 2M3, is a nonproducer; because it does not
contain M-MuLV, it has no superinfection barrier (44). A
positive cell line, M8, was derived by superinfection with
virus from NAp15-1 and then tested by pulse-labeling and
immunoblotting for synthesis and levels of the p15-deleted
protein. P75 was synthesized in amounts similar to those of
the endogenous P120, the Abelson transforming protein of
2M3 cells (Fig. 8). Immunoblotting showed undetectable
P75, whereas P120 was clearly present (Fig. 7, lane 5). Just
as in 70Z/3 cells, there appeared to be a marked instability of
the p15-deleted protein in 2M3 cells.
One possible reason for the difference in stability between
fibroblasts and lymphoid cells might be that the p15 se-




FIG. 6. Pulse-label of A-MuLV proteins in 70Z/3 cells. Cells
were washed in PBS (pH 7.5), grown in methionine-free medium for
1 h and resuspended at 5 x 107 cells per ml in 0.5 ml of methionine-
free medium containing 1 mCi of [35S]methionine per ml for 10 min
at 37°C. Cold PBS was added to stop the labeling. The cells were
extracted and immunoprecipitated with R-anti-abl, a rabbit anti-
serum provided by Jean Wang, prepared against v-abl protein
expressed in bacteria. The immunoprecipitates were analyzed by
SDS-7% polyacrylamide electrophoresis as described in the text.
The cell lines used are indicated above each lane. The positions of
the precipitated A-MuLV proteins are indicated.
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compartment. p15 is in fact the most hydrophobic of the gag
proteins and will partition partially in membranes (2, 35).
This is likely to be due in part to the fatty acid myristate,
which is covalently linked to the N terminus of p15 (10, 30).
The Abelson protein is also myristylated on its N terminus
due to its p15 sequences (29). We found that the first 34
amino acids of gag present in the gag-deleted Abelson
protein is sufficient for the protein to become myristylated
(unpublished data). To test whether the p15-deleted protein,
P75, fractionated differently than P90 in 7OZ/3 cells, we
fractionated 70Z/90A and 70Z/d2 cells and followed the
A-MuLV proteins by autophosphorylation (Fig. 9). The cells
were fractionated by 100,000 x g centrifugation into par-
ticulate (P100) and soluble (S100) fractions. These two
fractions were then immunoprecipitated and analyzed for
autophosphorylation activity. Although, again, the total au-
tophosphorylation activity of P75 was less than 1/20th that of
P90 (lanes 1 and 4), the activity that remained appeared to
fractionate in a similar manner to that of P90, with a ratio of
roughly 2:1 of P100 versus S100 activity (lanes 2, 3, 5, and 6).
Effect of v-abl deletions on lymphoid transformation. As
described above, A-MuLV genomes deleted in v-abl back
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FIG. 7. Immunoblotting of A-MuLV proteins. Cells (5 x 10i,
lanes 1 through 3, or 1 x 106, lanes 4 through 9) were extracted,
fractionated on an SDS-7% polyacrylamide gel, and transferred to
nitrocellulose as described in the text. After a blocking step, the
nitrocellulose filter was incubated with a 1:1,000 dilution of R-anti-
abl, washed, and incubated with peroxidase conjugated goat anti-
rabbit immunoglobulin G. After washing, the specific signal was
developed with 3-3'-diaminobenzidene. These steps are all de-
scribed in the text. The cell lines used are indicated above each lane
and described in the legend to Fig. 4. In addition, 2M3 is an
A-MuLV[P120]-transformed lymphoid line. M8 is a single-cell clone
of 2M3 cells infected with p15-deleted virus. In lane 9, 1/10th of the
lysate from 70Z/90A was mixed with 9/lOths of that from 70Z/M.




FIG. 8. Pulse-label of A-MuLV proteins in 2M3 cells. Cells were
pulse-labeled for 10 min with [35S]methionine and immunoprecipi-
tated with R-anti-abl as described in the legend to Fig. 6. The
immunoprecipitates were analyzed by SDS-7% polyacrylamide
electrophoresis in the standard fashion. The cell lines used are
indicated above each lane and described in the legend to Fig. 7. The
positions of A-MuLV proteins are marked.
both retain the ability to transform lymphoid cells, although
the efficiency is greatly reduced as compared with A-
MuLV[P160] (Table 1). These two plasmids, however, have
more of v-abl than is required for fibroblast transformation.
We have previously found (21) that a gag-deleted plasmid,
pAB-P, containing only the 5' 1.2 kilobases of v-abl, will
transform NIH/3T3 cells. As this plasmid was deleted in
gag, we could not test whether this minimum transforming
region was also sufficient for lymphoid transformation. For
this reason we constructed a plasmid containing gag fused to
the 5' 1.2 kilobases of v-abl. This plasmid, pABGP, is
exactly the same as pABN2, except that it extends to a PstI
site in v-abl rather than a Narl site (see above for details of
construction). The three plasmids pABGP, pABN2, and
pABX2 were identical, except that they contain 1,221, 1,484,
and 1,861 bases of v-abl, respectively. Plasmid pABGP
transformed NIH/3T3 cells as expected, and we established
a line, GP-2, from one of the foci. This line contains only the
expected genome and the predicted 80-kd Abelson protein
(data not shown).
We harvested virus from this line and tested it for lym-
phoid transformation. It was totally negative in an agar
colony assay. We next tested the virus by a liquid transfor-
mation method in which bone marrow cells are infected and
plated directly in liquid culture. This gives a greater sensi-
tivity because a single transformation event can overtake the
entire culture. The GP-2 virus was positive in this assay. Of
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FIG. 9. Fractionation of in vitro kinase activity in 70Z/3 cells.
Equal numbers of cells were swelled in hypotonic buffer and broken
in a Dounce homogenizer and by passage through a 25-gauge needle
as described in the text. Nuclei and unlysed cells were remnoved by
1,000 x g centrifugation. Half of the supernatant was saved and
represented the "total" fraction. The other half was fractionated by
100,000 x g centrifugation into particulate (P100) and soluble (S100)
fractions. The samples were immunoprecipitated with R-anti-abl,
assayed for in vitro autophosphorylation activity, and analyzed by
SDS-7% polyacrylamide electrophoresis as described in the text.
The cell lines and fractions used are indicated above each lane. (A)
1 h of exposure at room temperature; (B) 16 h of exposure of the
same gel at -70°C with an intensifying screen.
13 infected dishes, 3 became transformed. Virus derived
from X2B and N2 cells transformed almost 100% of dishes
infected (Table 2). The latency for the GP-2-infected plates
was substantially longer than that for the other viruses. We
checked two of the GP-2-transformed cultures for Abelson
proteins and found in each a protein of the same size as in
GP-2.
The low efficiency of the GP-2 virus may be a conse-
quence of the low virus titer as tested on NIH/3T3 cells.
GP-2 stocks were titered at 2 x 104 cells per ml, substantially
lower than other viruses. The titer was even lower for
another line derived from a focus transformed with pABGP.
The two liquid cultures transformed with GP-2 virus and
containing the expected protein showed clearly that this
protein is capable of transforming lymphoid cells. We sus-
pect that the GP-2 virus is intrinsically inefficient at lym-
phoid transformation, but the low titer of the stock makes
definitive statements difficult.
DISCUSSION
We have examined why a previously described large
deletion of gag-coding sequence from A-MuLV specifically
abolished lymphoid cell transforming activity (21). We found
that a deletion of only p15 sequences has the same dramatic
effect, implying a localization of the crucial sequence to this
subregion of gag. We further found that the p15 deletion
labilized the protein in two different lymphoid cells, implying
that the p15 sequences function to stabilize the protein
specifically in lymphoid cells.
Localization to p15. The large gag deletion studied previ-
ously brought the N-terminal 34 amino acids of gag next to
v-abl, and it could have been this specific juxtaposition of
sequences that affected lymphoid-transforming activity
rather than the loss of sequence due to deletion. This now
seems unlikely because the p15 deletion described here left
amino acids 1 to 37 (counting the initial methionine as
number 1) and 139 to 236 of gag intact. Thus, the deletion
left in place the 97 amino acids next to v-abl but had the
same effect. The specificity of the effect to p15 sequences is
indicated by the maintenance of lymphoid-transforming ac-
tivity in a p12 deletion mutant. Furthermore, the small
number of lymphoid transformants arising from infection of
bone marrow cells with the p15-deleted virus could be
accounted for by reacquisition of the p15 sequences, pre-
sumably via recombination with the helper virus. This again
emphasizes the requirement of these p15 sequences for
lymphoid transformation. Finally, a smaller deletion at the C
terminus of p15 (amino acids 114 to 138 in pNdl) also caused
a large reduction in lymphoid transformation, although there
was some residual activity (Table 1).
In searching for an explanation of the role of p15 se-
quences, we noted that p15 is the most hydrophobic of the
gag proteins and will partition into membranes (2, 35). In
part, this is probably due to the myristyl group covalently
linked to the N terminus of p15 (10). The A-MuLV protein is
also myristylated on the end of its sequences (29), but we
have found that the N-terminal 34 amino acids of gag still
present in the gag-deleted protein are sufficient for signaling
the myristylation (unpublished data), implying that signaling
myristylation is probably not the function of the required p15
sequence. In addition, fractionation of the proteins in lym-
phoid cells into particulate and soluble fractions by 100,000
x g centrifugation revealed no difference in localization of
the gag-deleted protein. As found for P16 ag-abI (40), both
the p15-deleted P75 and wild-type P90 proteins were present
in similar amounts in the particulate and soluble fractions.
The proteins not only localized similarly but are biochemi-
cally similar: in fibroblasts, both are phosphorylated on
tyrosine and are capable of causing an elevation of the
protein-bound phosphotyrosine level (21).
Instability in lymphoid cells. To examine whether there
might be differences between A-MuLV[P90] and the p15-
deleted A-MuLV[P75] specific to lymphoid cells, we in-
fected 70Z/3, a chemically induced pre-B lymphoma line
(20), with both viruses. The two viruses made similar
amounts of RNA in this line, ruling out the possibility that
p15 sequences seriously affect transcription or RNA stabil-
TABLE 2. Lymphoid transformation by A-MuLV variants
truncated at their C terminus
Agar Liquid
Fibroblast ~~~~No.ofdFelliebitebroblast LLymphoid culturesC Avg timedCell line titer Lymphoid conis ta- torn-
(FFU/ml)a colonies per per formed/ formation
FFU no. (days)
infected
54/C12(P160) 1 x 105 64 ± 4 128 ± 8 9/9 11
X2B(P100) 5 x 105 5 ± 2 2.0 ± 0.4 7/8 15
N2(P90) 6 x 105 27 3 9 1 7/7 12
GP-2(P80) 2 x 104 <0.5 ± 0.5 <2 ± 2 3/13 23
a The virus titers were determined on NIH/3T3 cells. FFU, Focus-forming
units.
b Nucleated bone marrow cells (2 x 106) were infected with 1.0 ml of virus
and plated in agar. Lymphoid colonies appear at 10 to 14 days postinfection.
The data are given as the average number of colonies ± the standard error of
the mean.
C Nucleated bone marrow cells (2 x 106) were infected with 1.0 ml of virus
and plated in liquid.
d The average time required to observe lymphoid transformants overtaking
the culture is given. Nontransformed cultures were held 35 to 40 days.
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ity. Pulse-labeling of the 70Z/3 lines showed that both
proteins were synthesized efficiently. There was, however, a
striking difference in autophosphorylation activity of P90
compared with P75. This was explained when electropho-
retic fractionation, and staining with peroxidase-coupled
antibody showed that the steady-state amount of P90 was
much higher than that of P75 in the 70Z/3 cell lines. By
contrast, in transformed fibroblast lines, P90 and P75 had
more similar amounts and autophosphorylation activities. In
an A-MuLV-induced lymphoid cell line, 2M3, the same
instability of the p15-deleted protein as in 70Z/3 cells was
evident. The results in these two cell lines show that in
lymphoid cells there is a specific instability of the p15-
deleted Abelson protein, which presumably explains the
inability of p15-deleted Abelson viruses to transform bone
marrow cells.
Importance ofgag sequence in A-MuLV. The large deletion
in gag (21) and now the smaller deletions within p15 have
shown that some of the gag sequences in A-MuLV are
integral parts of this transforming virus. These sequences
are required to stabilize the transforming protein in lym-
phoid cells. If the recombination event to form the virus had
occurred at amino acid 34 of p15, rather than within p30, our
data clearly indicate that the virus would not be transforming
and would never have been detected. (Remember that in
animals A-MuLV transforms lymphoid cells but not
fibroblasts.) Whether the inclusion of gag sequences (or
some other foreign sequence) is a necessary event in the
modification of the nononcogenic proto-oncogene, c-abl, to
form the v-abl oncogene is a more difficult question to
answer. Because the N terminus of c-abl is missing from
A-MuLV (37, 38), we do not know whether the gag se-
quence is replacing the normal function of the c-abl N-ter-
minal sequence or whether gag is imparting new properties
to the abl protein. B. Mathey-Prevot and D. Baltimore
(unpublished data) have shown that the N terminus of
pp60src will replace the gag function in A-MuLV lymphoid
transformation, showing that gag is not unique in providing
the stabilizing activity.
Although the deletion of the c-abl N terminus and its
replacement by gag sequence may be the events that acti-
vate c-abl to become the v-abl oncogene, there are other
differences between c-abl and v-abl. For one thing, there are
many point mutations in v-abl relative to c-abl which may be
important (38). Also, due to the strong retrovirus promoter,
there is an elevated expression of the Abelson transforming
protein over the c-abl product of ca. 14-fold (37). Any or all
of these alterations could be responsible for making c-abl
into an oncogene.
The reason p15 sequences stabilize the A-MuLV protein
specifically in lymphoid cells is not clear. Because p15 is
hydrophobic, we suspected that it might affect the localiza-
tion of the protein to the membrane. Crude fractionation by
100,000 x g centrifugation, however, suggests that, at least
for the autophosphorylation activity that remains, there is no
difference in localization. Perhaps there are more subtle
differences in localization, such as localization to specific
organelles or complexes which might stabilize the protein. A
simpler hypothesis is that deletion in p15 may simply de-
stabilize the protein due to changes in secondary structure
which make it more accessible to proteases. For this to be
true, either these proteases must be specific to lymphoid
cells or the change in secondary structure must not be as
pronounced in fibroblasts.
A final point made by these experiments is that the
minimum transforming region of v-abl is the same for
fibroblasts and lymphoid cells. The derivation of lymphoid
clones transformed by the GP-2 virus demonstrates this
point; it has a v-abl region with as small a deletion of v-abl
sequence as any that will transform fibroblasts (20a, 21). The
GP-2 virus is inefficient at transformation but also, for
unknown reasons, has a low titer. Previous data showed that
C-terminal v-abl sequences play a quantitative but not
qualitative role in A-MuLV transformation (21, 27); perhaps
GP-2 shows this effect most dramatically, but until higher-
titer stocks are available this point will remain unclear.
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